Tribenoside
(Synonyms: 三苄糖甙) 目录号 : GC49072
A vasoprotective agent
Cas No.:10310-32-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tribenoside is a vasoprotective agent with anti-allergic and anti-inflammatory activities.1,2 It inhibits agonist-induced contractions in various isolated porcine venous preparations when used at concentrations ranging from 10 to 30 µg/ml.1 Tribenoside inhibits compound 48/80-induced histamine release in isolated rat peritoneal cells (EC50 = 10 µg/ml).3 It reduces decreases in proteoglycan levels and the severity of cartilage destruction in the inflamed joints in a rabbit model of surgically induced osteoarthritis when administered at doses of 100 and 200 mg/kg per day.4 Formulations containing tribenoside have been used in the treatment of hemorrhoids and varicose veins.
1.Jaques, R.The activity pattern, in isolated veins, of a benzyl glucofuranoside derivative possessing combined anti-inflammatory and venotropic effectsPharmacology4(4)193-202(1970) 2.Jaques, R.The pharmacological activity of tribenosidePharmacology15(5)445-460(1977) 3.RÜegg, M., and Jaques, R.Tribenoside as an inhibitor of chemically induced histamine releaseExperientia30(4)399-401(1974) 4.Colombo, C., Butler, M., Hickman, L., et al.A new model of osteoarthritis in rabbits. II. Evaluation of anti-osteoarthritic effects of selected antirheumatic drugs administered systemicallyArthritis Rheum.26(9)1132-1139(1983)
| Cas No. | 10310-32-4 | SDF | |
| 别名 | 三苄糖甙 | ||
| Canonical SMILES | O[C@H]([C@H]1OCC2=CC=CC=C2)C(OCC)O[C@]1([H])[C@@H](COCC3=CC=CC=C3)OCC4=CC=CC=C4 | ||
| 分子式 | C29H34O6 | 分子量 | 478.6 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0894 mL | 10.4471 mL | 20.8943 mL |
| 5 mM | 0.4179 mL | 2.0894 mL | 4.1789 mL |
| 10 mM | 0.2089 mL | 1.0447 mL | 2.0894 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence
Eur Rev Med Pharmacol Sci 2016 Jun;20(12):2742-51.PMID:27383331doi
Objective: The combination of Tribenoside+lidocaine (Procto-Glyvenol®) is a medical preparation for the local treatment of hemorrhoids, delivered as a suppository or rectal cream. This product has been used for decades in the therapy of hemorrhoids. This review discusses available evidence on the use of Tribenoside/lidocaine in clinical practice. Materials and methods: Papers were retrieved by a PubMed search, using different combinations of pertinent keywords (e.g. Tribenoside AND hemorrhoids), without any limitations in terms of publication date and language. Documents from Authors' personal collection of literature could also be considered. Papers were selected for inclusion according to their relevance for the topic, as judged by the Authors. Results: The efficacy of the combination of Tribenoside+lidocaine in relieving symptoms caused by hemorrhoids and its safety have been assessed in several clinical studies on patients of either gender, either versus its two individual components (Tribenoside and lidocaine) or versus steroids in the same setting. Five studies compared the combination treatment with each of its single components, and of these, three studies compared Tribenoside+ lidocaine with a tribenoside-free semi-placebo preparation containing only lidocaine, and two studies compared this combination with lidocaine-free preparations containing only Tribenoside. Tribenoside+lidocaine was compared with steroid-containing preparations in six studies. Last, two studies evaluated the efficacy and tolerability of the Tribenoside+lidocaine combination in women with hemorrhoids as a consequence of pregnancy or delivery. All the above-mentioned studies were well-conducted and can provide a comprehensive evaluation of Tribenoside+lidocaine in the treatment of hemorrhoids. Conclusions: Enough evidence exists to recommend the use of this combination therapy as a fast, effective and safe option for the local treatment of low-grade hemorrhoids.
Hemorrhoid management in women: the role of Tribenoside + lidocaine
Drugs Context 2019 Sep 13;8:212602.PMID:31555338DOI:10.7573/dic.212602.
Hemorrhoids are commonly reported in women. However, despite the high prevalence of hemorrhoids in women and the major impact of this condition on quality of life, specific evidence and recommendations on the treatment of hemorrhoids in women are scant. This paper reviews various options in current therapy for hemorrhoids in women-namely, medical intervention (topical and systemic drug therapy)-and discusses the available clinical evidence for an appropriate use of over-the-counter topical formulations for the symptomatic treatment of hemorrhoids. Its focus is on a medical preparation containing Tribenoside + lidocaine, available as a rectal cream (Tribenoside 5%/lidocaine 2%) and a suppository (Tribenoside 400 mg/lidocaine 40 mg) and marketed under the brand Procto-Glyvenol® (Recordati, SpA, Italy). Given its rapid comprehensive efficacy on all the different symptoms of hemorrhoids, the Tribenoside + lidocaine combination can find a place in the treatment of this hemorrhoidal disease. Importantly, its efficacy and tolerability have been formally evaluated in several well-conducted studies, some of which were specifically conducted in women. In particular, Tribenoside + lidocaine can be safely administered in postpartum women and in pregnant women after the first trimester of pregnancy. In pregnant women, the Tribenoside/lidocaine combination significantly improved both subjective and objective symptoms of hemorrhoids. Fast onset of symptom relief was reported from 10 minutes after administration, lasting up to 10-12 hours. On these bases, Tribenoside + lidocaine can represent a fast, effective, and safe option to treat hemorrhoids when conservative therapy is indicated, and it deserves consideration as a first-line treatment of this disease in clinical practice.
[Modern trends in combined treatment of hemorrhoids: topical form Tribenoside + Lidocaine and phlebotonic Ginkgo biloba + Troxerutin + Heptaminol]
Khirurgiia (Mosk) 2022;(12. Vyp. 2):90-97.PMID:36562679DOI:10.17116/hirurgia202212290.
Acute hemorrhoids are the most common reason for referring to coloproctologist in people of working age. In the modern world, food culture and lifestyle are the most prominent factors leading to the risk of hemorrhoids. In the 21st century, it is hard to overestimate an importance of potential employability and active social role regarding socio-economic well-being. This thesis applies to patients suffering from proctological diseases, and those with hemorrhoids prevail among these ones. Minimally invasive treatment and pharmacotherapy defined primary needs of patients, i.e. treatment should be quick, safe and effective. Favorable treatment outcomes are possible only in pathogenetic therapy. In this review, we will define the priorities in effective combined treatment of hemorrhoids.
The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells
Biol Pharm Bull 2010;33(2):307-10.PMID:20118558DOI:10.1248/bpb.33.307.
Tribenoside has been used clinically for hemorrhoidal disease associated with coagulation, inflammation, and wounds. However, the pharmacological mechanism of Tribenoside activity has never been clear. In this study we examined whether Tribenoside affected expression and deposition of laminins that are required for reconstruction of basement membranes (BMs) during wound healing in hemorrhoidal disease. HaCaT cells, which are derived from human epidermis, were treated in growth media supplemented with Tribenoside. Reverse transcriptase-polymerase chain reaction (RT-PCR) using primers specific for laminin chains showed that HaCaT cells constitutively expressed laminin alpha3, alpha5, beta1, beta3, gamma1, and gamma2 chains. Tribenoside treatment of HaCaT cells did not induce expression of other laminin chains. We also quantified the expression of laminin chains in tribenoside-treated cells using real-time PCR. The expression level of laminin alpha3, beta1, beta3, gamma1, and gamma2 chains was not affected. In contrast, the expression of laminin alpha5 in the tribenoside-treated cells was four times higher than that of control cells. Immunocytochemistry also showed that Tribenoside accelerated the focal deposition of laminin-332 (alpha3, beta3, gamma2). These results suggest that Tribenoside interacts with epidermal cells and regulates the expression and localization of laminins to help reconstruct BMs in wound healing of hemorrhoids.
The pharmacological activity of Tribenoside
Pharmacology 1977;15(5):445-60.PMID:578928DOI:10.1159/000136721.
Ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside (RBGF) the active substance of Glyvenol displays a unique spectrum of activities. It possesses anti-inflammatory, mild analgesic, antitoxic, wound-healing, fibrinolysis-promoting, anti-arthrotic, amine-release-inhibitory, membrane-stabilizing and venotropic properties. Unlike corticosteroids or nonsteroidal anti-inflammatory agents, TBGF dose not exert untoward effects on the gastrointestinal system, the connective tissue or the body's defence systems. In addition, TBGF does not affect the prostaglandin-synthetase system. TBGF thus seems to share the positive pharmacological properties ascribed to glucocorticoids and non-steroidal anti-inflammatory agents, yet is free from the undesirable effects of both.